NEW YORK, NY / ACCESSWIRE / February 25, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rhythm Pharmaceuticals, Inc. ("Rhythm" or the "Company") (NASDAQ:RYTM). Investors who purchased Rhythm securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/rytm.
The investigation concerns whether Rhythm and certain of its officers and/or directors have violated federal securities laws.
On February 24, 2022, Rhythm issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in adult and pediatric patients 6 years of age and older with Bardet-Biedl Syndrome (BBS) or Alström syndrome." Rhythm advised investors that "[o]n February 23, the FDA notified the Company that the Prescription Drug User Fee Act (PDUFA) goal date has been revised to June 16, 2022." On this news, Rhythm's stock price fell $1.11 per share, or 13.26%, to close at $7.26 per share on February 24, 2022.
If you are aware of any facts relating to this investigation or purchased Rhythm shares
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC